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Pregnancy represents a physiologic hypercoagulable state. The presence of inherited 
thrombophilias (factor V Leiden, prothrombin G20210A mutation, deficiencies of 
protein C, protein S and antithrombin) or acquired thrombophilias (antiphospholipid 
syndrome) increases the risk for venous thromboembolism, which represents one of 
the most common causes of direct maternal death. The clinical diagnosis of thrombosis 
can be difficult because of the overlap of symptoms with pregnancy-related 
manifestations. Antiphospholipid syndrome is correlated with early and late pregnancy 
complications whereas the association between the inherited thrombophilias and 
adverse pregnancy outcomes is still controversial. The psychological impact of 
thrombophilia in pregnancy should be also taken into consideration to prevent the 
negative effects of anxiety and stress on mother’s health and on birth outcomes. 
Thrombophilia testing in pregnancy is recommended only in cases in which the result 
is likely to influence the therapeutic decision. Low-molecular-weight heparins are the 
preferred anticoagulant for prophylaxis and therapy of thromboembolic events in 
pregnancy, presenting a low incidence of side effects. Future research is required to 
establish the optimal therapeutic strategy in pregnant women with thrombophilia, 
based upon a better stratification, in order to prevent thromboembolism and to 
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INTRODUCTION
Thrombophilia or hypercoagulability, defined as the 
tendency to develop thrombosis, can be secondary to 
hereditary and acquired causes. The physiologic 
prothrombotic changes and the additional effect of 
thrombophilic factors represent commonly the 
background of pregnancy-related thrombosis.1 
Inherited thrombophilia is a consequence of a loss of 
function mutations (which result in reduced or 
abolished protein function) such as deficiencies of anti-
thrombin, protein C, protein S, and/or a gain of function 
mutations (which result in new or enhanced protein 
activity) such as prothrombin G20210A mutation and 
Factor V Leiden (FV Leiden). Although some studies 
have shown the contribution of inherited thrombophilia 
to an adverse pregnancy outcome (e.g. preeclampsia, 
placental abruption, intrauterine growth delay, fetal 
loss) the association is still controversial. The main 
acquired thrombophilia associated with an increased 
thrombotic risk and pregnancy complications such as 
recurrent fetal loss, fetal death, preeclampsia and 
intrauterine growth restriction, is represented by the 
anti-phospholipid syndrome (APS) [1]. 
The purpose of this paper is to review the effects of 
thrombophilia in pregnancy (the increased thrombotic 
risk, adverse pregnancy outcomes, and psychological 
impact) and the strategies for thromboprophylaxis and 
therapy. 
Pregnancy Morbidity and Mortality Associated 
With Thrombosis 
Pregnancy is associated with a 5-10 fold increased risk of 
venous thromboembolism (VTE); the risk is highest 
immediately postpartum being about 20-fold greater 
than that of non-pregnant women [2]. The incidence of 
VTE is estimated to be approximately 0.5–2.2/ 1000 
deliveries [2]. A recent prospective cohort study that 
included 1.3 million pregnant women identified the 
following risk factors for pregnancy-related VTE: 
increased maternal age, hyperemesis, multiple gestation, 
infection, hospitalization and obesity [3]. A prior 
episode of VTE also significantly increases the 
thrombotic risk in pregnancy, with an estimated rate of 
VTE recurrence of 10.9% [1]. 
VTE, including both deep venous thrombosis (DVT) 
and pulmonary embolism (PE) is potentially life-
threatening condition. The World Health Organization 
mortality database found embolism accounts for 3.2% of 
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global maternal deaths [4]. VTE is the leading cause of 
direct maternal death in the United Kingdom and one of 
the most common causes in the European Union, 
according to EURO-PERISTAT project, which 
includes reports from 26 European countries [5, 6]. A 
recent observational study, that used data from the 
Pregnancy Mortality Surveillance System, shows that 
the 2011-2013 pregnancy-related mortality ratio was 
17.0 deaths/ 100,000 live births in the United States and 
VTE accounted for 9.2% of all pregnancy-related deaths 
[7]. 
Physiopathology of Prothrombotic State 
during Pregnancy 
Hypercoagulability, venous stasis and vessel damage – 
known as Virchow’s triad- represent the mechanisms 
leading to the occurrence of VTE. The hypercoagulable 
state in pregnancy, representing an adaptive transient 
mechanism in preparation for hemostasis during birth, 
results from a progressive increase in the levels of 
Factors VII, VIII, X and fibrinogen throughout 
pregnancy, with a peak at delivery, and a decrease in 
protein S, antithrombin and fibrinolysis [8]. An 
acquired activated protein C resistance may be found in 
40% of pregnant women. D-dimer levels, with a 
threshold of 1.0 mg/L up to week 30 of pregnancy and, 
respective, 2.0 mg/L just prior to delivery, peaks on the 
first day postpartum and then decrease, indicating that 
the coagulation and fibrinolytic systems begin to return 
to the baseline [9]. However, a procoagulant state lasts 
for 6-8 weeks after giving birth or longer, up to 12 weeks 
postpartum [8, 9]. 
Venous stasis is due to several mechanisms such as: the 
vasodilatation induced by pregnancy-related hormones, 
decreased venous tone, increased venous pressure, 
reduced venous flow velocity and compression of the 
left iliac vein [10, 11]. The supine position may also lead 
to the compression of the inferior cava vein by the 
enlarged uterus. The improvement of venous outflow 
and capacitance occurs usually 3 months postpartum. 
Pelvic veins may suffer a degree of endothelial damage 
during the vaginal or caesarian delivery [11]. 
Clinical Implications of Thrombophilia in 
Pregnancy 
1. VTE 
Pregnancy-related VTE is manifested as DVT in 75–
80% of the cases; an underlying thrombophilic factor 
may be found in half of these situations [1, 11]. 
Hereditary thrombophilia increases the thrombotic risk 
in pregnancy up to 34-fold [12]. DVT presents two 
peculiar aspects in pregnancy: it occurs predominantly 
in the left lower limb (90% versus 55% in non-pregnant 
women) and especially at the proximal level (72% at the 
iliofemoral veins versus vs. 9% in non-pregnant women) 
leading to an increased risk of PE [11].11 DVT 
episodes, equally distributed across the three trimesters 
of pregnancy, occur in prenatal period in two thirds of 
the cases [11]. 
PE may occur in 20–25% of women who have untreated 
DVT and may be fatal in 15% of pregnant women, of 
whom 66% may die within half an hour from the 
thromboembolic event [13]. 
Based on the relative thrombotic risk, the inherited 
thrombophilias have been classified as: low-risk 
thrombophilias such as heterozygosity for FV Leiden, 
heterozygosity for prothrombin G20210A mutation, 
deficiencies of protein S and C, and high-risk 
thrombophilias: homozygosity for FV Leiden, 
homozygosity for prothrombin G20210A mutation, 
compound heterozygosity for FV Leiden and 
prothrombin mutation, and antithrombin deficiency 
[1]. However, a recent systematic review and meta-
analysis has shown that protein C and protein S 
deficiencies represent high risk thrombophilias in 
pregnancy whereas the compound heterozygosity for 
FV Leiden and prothrombin G20210A mutation 
present a lower absolute risk of VTE [12]. 
Other inherited thrombophilias, 
methylenetetrahydrofolate reductase polymorphisms 
C677T and A1298C, leading to 
hyperhomocysteinemia, are not associated with VTE in 
pregnancy, partly explained by the routinely 
administration of folic acid supplements which reduce 
homocysteinemia [1, 8]. 
FV Leiden and protrombin G20210A mutation 
represent the most common inherited thrombophilias 
(with the highest prevalence in South Europe) whereas 
protein S, protein C and antithrombin deficiencies are 
rare in general population [1, 14]. The genetic 
background, the prevalence and the pregnancy-related 
thrombotic risk of inherited thrombophilias are 
summarized in Table 1.  
The diagnosis of VTE is difficult, because of the overlap 
of symptoms with those which are commonly 
pregnancy-related: pain and edema of the lower limb, 
tachycardia and dyspnea [10, 15]. The pretest 
probability of DVT in pregnancy is assessed using the 
“LEFt” decision rule, based upon the presence of the 
following symptoms: left leg location, edema with at 
least 2 cm circumference difference between calves and 
the occurrence in the first trimester [10]. Compression 
duplex ultrasound  is the primary diagnostic test for 
DVT; in case of suggestive symptoms and negative 
findings, the test should be repeated or, if the results are 
equivocal and iliac vein thrombosis is suspected, 
magnetic resonance imaging or venography are 
recommended [13, 16]. Recent data show that the 
exposure to MRI is safe during the first trimester of 
pregnancy whereas gadolinium MRI at any time of 
pregnancy is associated with an increased risk of harm to 
the fetus, stillbirth or neonatal death [17]. The 
measurement of D-dimer, increased with large 
individual fluctuation during pregnancy, is not 
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recommended as a screening tool to exclude VTE in 
pregnancy [9, 13, 16]. 
The clinical diagnosis of PE is suggested by the sudden 
occurrence of symptoms such as: dyspnea, pleuritic 
chest pain, tachypnea, tachycardia, unexplained 
hypotension, hemoptysis, cough. When PE is suspected 
and in the presence of manifestations of DVT, duplex 
ultrasound of the lower limbs is indicated and the 
anticoagulant therapy should be administrated if the 
result is positive; in the absence of manifestations of 
DVT or a negative result, a ventilation/perfusion lung 
scan or a computerized tomography pulmonary 
angiogram should be performed, according to the recent 
guidelines [13, 16]. Although chest X-rays findings are 
not specific or sensitive for PE, the examination is useful 
for the pregnant women. The selection of women with 
normal results at chest X-rays for ventilation/perfusion 
scan increases the rate of diagnostic result comparatively 
to computerized tomography pulmonary angiogram 
(94% versus 70%) whereas those with abnormal chest 
X-rays present higher non-diagnostic result rate with 
ventilation/perfusion scan than computerized 
tomography pulmonary angiogram (40% versus 16.4%) 
[13, 16]. Although the fetal exposures are below the 
threshold for malformations 100–200 mGy, 
computerized tomography pulmonary angiogram is 
associated with a relatively high dose of radiation to the 
mother’s breast tissue, leading to an increase of the 
lifetime risk of breast cancer by 13.6% [11, 13]. The 
ventilation/perfusion scan should be recommended for 
young women with a family history of breast cancer or 
previous chest computerized tomography [13]. 
 
Table 1.  Inherited Thrombophilias: Genetic Background, Prevalence and Pregnancy-Related Risk of VTE 
Thrombophilia Genetic background Prevalence in 
healthy population 
(%) [1, 13] 
Relative risk of 
pregnancy-related VTE 
(%) [1, 2] 
Absolute risk of 
pregnancy-related 
VTE (%) [12] 
FV Leiden Guanine to adenine substitution at 







Guanine to adenine substitution at 
nucleotide 20210 in the 3' 
untranslated region of the 
prothrombin gene 






Mutations leading to a quantitative 
deficiency (type I) or functional 
deficiency (type II). 
0.2 4.8 7.8 
Protein S 
deficiency 
Mutations leading to decreased levels 
or impaired function 
0.03- 0.13 3.2 4.8 
Antithrombin 
deficiency 
Mutations leading to decreased levels 
(type I of deficiency) or reduced 
activity (type II of deficiency) 
0.02- 0.2 4.7 16.6 
Abbreviations: VTE: venous thromboembolism, FV Leiden: Factor V Leiden 
 
 
The electrocardiogram may be more useful for the 
diagnosis of PE in pregnancy than in non-pregnant 
patients, since almost half of the pregnant women with 
acute PE present abnormalities such as: inverted T 
wave, S1Q3T3 pattern and right bundle branch block 
[11]. The arterial blood gas measurements are of limited 
value in pregnancy-related VTE, showing often normal 
results in the absence of massive PE [11, 13]. 
2. Adverse Pregnancy Outcomes 
Although numerous case-control studies have shown a 
link between inherited thrombophilia and adverse 
pregnancy outcomes such as: pre-eclampsia, placental 
abruption, fetal growth restriction, stillbirth and 
recurrent pregnancy loss, prospective cohort studies 
failed to confirm a cause-effect association. A weak 
association has been found between FV Leiden, 
prothrombin mutation, protein S deficiency and 2nd or 
3rd trimester pregnancy loss as well as for FV Leiden, 
prothrombin mutation and recurrent 1st trimester loss 
[1, 11, 14]. 
APS is the most important acquired thrombophilic 
factor manifested with recurrent venous and arterial 
thromboses and/or early and late pregnancy 
complications (recurrent miscarriage, fetal growth 
restriction, preeclampsia, premature birth, 
oligohydramnios, placental insufficiency and 
intrauterine death) along with persistent anti-
phospholipid antibodies including lupus anticoagulant, 
anti-β2-glycoprotein I, and/or anti-cardiolipin 
antibodies [18]. Although venous thrombosis is located 
mainly at the lower limbs, it may occur in unusual 
territories. Lupus anticoagulant presents the strongest 
association with thrombosis; the estimated relative risk 
of VTE for pregnant women with APS is 15.8 [1]. It has 
been shown that immunoglobulin G anti-
β2glycoprotein I-domain1 antibodies are associated 
with an increased thrombotic risk and obstetrical 
complications [18]. 
The pregnancy morbidity in women in the absence of 
thrombotic manifestations and/or history of 
thrombosis defines the obstetric APS. Catastrophic 
APS, the most severe form of APS, may also occur in 
pregnancy and postpartum and is manifested with 
multiple thromboses and multiorgan failure [18]. 
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Thromboprophylaxis in Pregnancy 
It has been shown that universal as well as selective 
thrombophilia screening, except for antiphospholipid 
syndrome, is not cost-effective for placenta-mediated 
pregnancy complications [19, 20]. Ideally, 
thrombophilia should be tested when the patient is not 
pregnant, does not have an acute VTE, before the 
administration of anticoagulants and when the results 
are likely to influence the medication [2, 16, 20]. 
Thromboprophylaxis in pregnancy should be 
considered in cases with thrombotic risk high enough to 
benefit from this therapy [2, 19, 20]. The factors 
contributing to an increased risk of VTE include: 
personal and family history of VTE, thrombophilia, 
prolonged immobilization, obesity, pregnancy 
complications and medical co-morbidities [2, 16, 19]. 
There is no firm recommendation regarding 
thromboprophylaxis in pregnancy, since the lack of 
consensus of the current guidelines [2, 12]. Considering 
the patient-centered medical approach, an individual 
risk-benefit is recommended to be assessed, taking also 
into account the patient’s preferences [2]. 
Based on recent data, thromboprophylaxis in pregnancy 
may be recommended in cases with family history of 
VTE and deficiency of antithrombin, protein C, or 
protein S as well as in women homozygous for FV 
Leiden with a positive family history and additional risk 
factors for VTE [12]. 
Thromboprophylaxis should be commenced early in the 
pregnancy and continued up to 6 weeks postpartum 
with anticoagulants that do not cross placenta, such as 
unfractionated heparin or low-molecular-weight 
heparin (LMWH) which presents a better safety profile 
[13, 16, 19]. Vitamin K antagonists cross the placenta 
and may affect the fetus (resulting in coumarin 
embryopathy and increased risk of intracranial 
hemorrhage before birth) and therefore they should not 
be administrated in pregnancy; the risk of embryopathy 
is eliminated if the medication is discontinued before 
the 6th week of gestation [2]. The recommended 
prophylactic and therapeutical doses of LMWH are 
summarized in Table 2. High risk situations such as APS 
may require the administration of intermediate doses 
that can be double than prophylactic doses [2]. 
 
Table 2. Prophylactic and Therapeutic Doses of LMWH [13, 16, 19] 
LMWH Prophylactic doses Therapeutic doses 
Dalteparin 5000 Uw once daily 200U/kg. once daily or 100U/kg. twice daily 
Tinzaparin 4500 U once daily 175U/kg once daily 
Enoxaparin 40 mg once daily 1mg/kg mg twice daily 
Nadroparin 2850 U once daily 171 U/kg once daily or 86 U/kg. twice daily 
Abbreviation: LMWH: low-molecular-weight heparin 
 
Mechanical prophylaxis with elastic stockings or 
intermittent pneumatic compression may be considered 
in hospitalized women when LMWH are 
contraindicated. Although it has been shown that 
thromboprophylaxis decreases the risk of VTE in 
pregnancy, recent data of a systematic review reveal that 
LMWH do not appear to influence the risk of recurrent 
placenta-mediated pregnancy complications: pre-
eclampsia, late pregnancy loss, and birth of a small-for-
gestational-age neonate; however, the same study shows 
that LMWH decreases the risk of recurrent placental 
abruption in at-risk women [21]. 
Treatment of Pregnancy-Related VTE  
The occurrence of an episode of VTE in pregnancy 
requires promptly therapeutic anticoagulation with 
LMWH; there is no consensus regarding the optimal 
doses and the timing of administration: once or twice 
daily [2]. Although the increase in glomerular filtration 
rate and in patient’s weight during pregnancy may justify 
the adjustment of LMWH dose, many studies have 
shown that few pregnant women require this in order to 
maintain proper anti-Xa levels. The monitoring of anti-
Xa levels is not routinely indicated and should be 
performed only in women with renal failure and in those 
with morbid obesity or very low weight [13]. 
Therapeutic doses of LMWH are effective in pregnancy-
related VTE, with an associated risk of recurrent VTE of 
1.15% [11]. The once-daily LMWH dosing schedule 
does not appear to be associated with a higher risk of 
VTE recurrence comparatively to twice-daily regimen 
[2]. There is no data showing a greater efficiency of one 
LMWH comparatively to others [2, 16, 19]. In case of 
renal impairment, Enoxaparin is the LMWH of choice; 
in severe cases with a creatinine clearance less than 30 
mL/min, unfractionated heparin is recommended [2]. 
The minimum duration of the anticoagulation with 
LMWH is usually 3 months in pregnancy and 6 weeks 
postnatal [2]. The therapeutic dose of LMWH can be 
maintained throughout this period or it could be 
reduced to an intermediate dose after several weeks (less 
than 75 % of a full dose but greater than prophylactic 
dose), especially in case of distal DVT or in women at 
risk of hemorrhage and osteoporosis [2]. 
The therapy may be adjusted based on individual risk 
factors such as cesarean delivery, immobility, obesity, 
obstetric complications, previous VTE, family history of 
VTE [16]. LMWH are associated with a lower risk of 
side-effects (bleeding, osteoporosis, heparin-induced 
thrombocytopenia) compared with unfractionated 
heparin [2, 13]. 
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Unfractionated heparin is administrated in pregnant 
patients with massive PE and in those with severe renal 
impairment, initially as a bolus intravenous 80 U/kg, 
followed by continuous infusion 18 U/kg and adjusted 
for an activated partial thromboplastin time at 1.5-2.5 
times baseline; the therapy continues either with 
unfractionated heparin administrated subcutaneously 
150 - 200 U/kg twice daily either with LMWH in 
therapeutic doses [13, 16, 19]. 
The new oral anticoagulants, such as direct thrombin 
inhibitors (dabigatran), and factor Xa inhibitors 
(rivaroxaban, apixaban, and edoxaban) may cross the 
placenta and should be avoided in pregnancy [13, 16]. 
Danaparoid and fondaparinux are heparanoid 
molecules and may be a therapeutic option for pregnant 
women with allergy to heparins or heparin-induced 
thrombocytopenia [11, 16]. 
Thrombolytic therapy with streptokinase, r-tPA or 
urokinase is indicated only in life-threatening VTE, e.g. 
massive PE with hemodynamic instability [13, 16]. 
Vena cava filters are rarely used in pregnant women and 
may be considered in case of acute PE within 2 weeks 
after delivery or recurrent VTE despite therapeutic 
anticoagulation [11]. 
The use of graded compression stockings in pregnant 
women with DVT may be indicated for the relief of the 
symptoms; recent studies failed to prove the benefit in 
the prevention of the post-thrombotic syndrome and 
the decrease in the recurrence rate of VTE in non-
pregnant patients [13, 16]. 
Psychosomatic Perspective 
Thrombophilia in pregnant women is also associated 
with an important psychological impact and requires 
counseling about the increased risk of thrombosis and 
possible adverse pregnancy outcome [20]. Pregnant 
women coping with thrombophilia face difficulties 
because of the emotional component of the diagnosis 
and treatment (fear, anxiety), associated with the sense 
of uncertainty and the need for professional support 
[22]. 
There is growing evidence that negative affective states 
(anxiety, depression) and stress exposure of the mother 
during pregnancy have implications on the birth 
outcomes (e.g. preterm birth, low birth weight) as well 
as on the child's subsequent neurodevelopment and 
health [23]. The identification of the signs of depression 
and/or anxiety should be also taken into consideration 
in the assessment of thrombophilia and pregnancy-
related VTE. 
The management of thrombophilia and VTE in 
pregnancy is complex and may require a 
multidisciplinary team involving obstetrician, midwife, 
geneticist, cardiologist, psychologist [13, 24]. 
Future Directions  
Further studies are required in order to clarify the 
optimal therapeutic strategy in pregnant women with 
thrombophilia, in order to prevent and treat VTE as well 
as to improve the pregnancy outcome. The ongoing 
randomized controlled trials may offer some pertinent 
answers: the Highlow study and ALIFE2 study, which 
investigate two dosing regimens of LMWH in pregnant 
women with a history of VTE, respective the effect of 
LMWH on live birth in patients with inherited 
thrombophilia and history of at least two miscarriages 
[25]. Although it has been shown that inherited 
thrombophilia has no significant contribution to 
adverse pregnancy outcomes, the complex 
physiopathologic mechanisms of this relationship are 
not completely clarified. Research is required to identify 
possible biomarkers (e.g. ANXA5 M2 haplotype) for 
the stratification of the risk and a better-targeted 
antithrombotic therapy [8, 20]. Further investigations 
may take also into consideration the bio-psychosocial 
model, to detect better the symptoms of anxiety, 
depression and stress in pregnant women with 
thrombophilia, which may overlap, creating difficulties 
in screening and intervention. 
CONCLUSIONS 
Thrombophilia in pregnancy represents a complex 
condition associated with increased risk of VTE and 
psychological implications. However, thrombophilia 
testing in pregnancy is recommended only when the 
results may influence the therapeutical decision. Further 
studies are required to release firm recommendations 
for thromboprophylaxis and anticoagulant therapy in 
pregnancy-related VTE. 
REFERENCES 
1. Battinelli EM, Marshall A, Connors JM. The role of 
thrombophilia in pregnancy. Thrombosis. 2013;2013:516420. 
doi: 10.1155/2013/516420 pmid: 24455235 
2. Bates SM, Middeldorp S, Rodger M, James AH, Greer I. 
Guidance for the treatment and prevention of obstetric-
associated venous thromboembolism. J Thromb 
Thrombolysis. 2016;41(1):92-128. doi: 10.1007/s11239-015-
1309-0 pmid: 26780741 
3. Virkus RA, Lokkegaard E, Lidegaard O, Langhoff-Roos J, 
Nielsen AK, Rothman KJ, et al. Risk factors for venous 
thromboembolism in 1.3 million pregnancies: a nationwide 
prospective cohort. PLoS One. 2014;9(5):e96495. doi: 
10.1371/journal.pone.0096495 pmid: 24788753 
4. Say L, Chou D, Gemmill A, Tuncalp O, Moller AB, Daniels J, 
et al. Global causes of maternal death: a WHO systematic 
analysis. Lancet Glob Health. 2014;2(6):e323-33. doi: 
10.1016/S2214-109X(14)70227-X pmid: 25103301 
5. Nair M, Knight M. Maternal Mortality in the UK 2011-13: 
Surveillance and Epidemiology. In: Knight M, Tuffnell D, 
Kenyon S, Shakespeare J, Gray R, Kurinczuk JJ, editors. On 
behalf of MBRRACE-UK Saving Lives, Improving Mothers' 
Care - Surveillance of maternal deaths in the UK 2011-13 and 
lessons learned to inform maternity care from the UK and 
Ireland Confidential Enquiries into Maternal Deaths and 
Morbidity 2009-13. London: Oxford, National Perinatal 
Epidemiology Unit, University of Oxford 2015. 
6. Bouvier-Colle MH, Mohangoo AD, Gissler M, Novak-Antolic 
Z, Vutuc C, Szamotulska K, et al. What about the mothers? An 
analysis of maternal mortality and morbidity in perinatal health 
surveillance systems in Europe. BJOG. 2012;119(7):880-9; 
Hotoleanu  International Journal of Cardiovascular Practice 
6 
discussion 90. doi: 10.1111/j.1471-0528.2012.03330.x pmid: 
22571748 
7. Creanga AA, Syverson C, Seed K, Callaghan WM. Pregnancy-
Related Mortality in the United States, 2011-2013. Obstet 
Gynecol. 2017;130(2):366-73. doi: 10.1097/AOG.000000 
0000002114 pmid: 28697109 
8. Ormesher L, Simcox L, Tower C, Greer IA. Management of 
inherited thrombophilia in pregnancy. Womens Health 
(Lond). 2016;12(4):433-41. doi: 10.1177/17455057166537 
02 pmid: 27638899 
9. Hedengran KK, Andersen MR, Stender S, Szecsi PB. Large D-
Dimer Fluctuation in Normal Pregnancy: A Longitudinal 
Cohort Study of 4,117 Samples from 714 Healthy Danish 
Women. Obstet Gynecol Int. 2016;2016:3561675. doi: 
10.1155/2016/3561675 pmid: 27190521 
10. Soma-Pillay P, Nelson-Piercy C, Tolppanen H, Mebazaa A. 
Physiological changes in pregnancy. Cardiovasc J Afr. 
2016;27(2):89-94. doi: 10.5830/CVJA-2016-021 pmid: 
27213856 
11. Simcox LE, Ormesher L, Tower C, Greer IA. Pulmonary 
thrombo-embolism in pregnancy: diagnosis and management. 
Breathe (Sheff). 2015;11(4):282-9. doi: 10.1183/20734735.0 
08815 pmid: 27066121 
12. Croles FN, Nasserinejad K, Duvekot JJ, Kruip MJ, Meijer K, 
Leebeek FW. Pregnancy, thrombophilia, and the risk of a first 
venous thrombosis: systematic review and bayesian meta-
analysis. BMJ. 2017;359:j4452. doi: 10.1136/bmj.j4452 pmid: 
29074563 
13. Royal College of Obstetricians and Gynaecologists. 
Thromboembolic Disease in Pregnancy and the Puerperium: 
Acute Management; Green-top Guideline No. 37b. 2015 
[updated 2015; cited 2019]. Available from: 
https://www.rcog.org.uk/globalassets/documents/guideline
s/gtg-37b.pdf. 
14. Liatsikos SA, Tsikouras P, Manav B, Csorba R, von Tempelhoff 
GF, Galazios G. Inherited thrombophilia and reproductive 
disorders. J Turk Ger Gynecol Assoc. 2016;17(1):45-50. doi: 
10.5152/jtgga.2016.15212 pmid: 27026779 
15. Khan F, Vaillancourt C, Bourjeily G. Diagnosis and 
management of deep vein thrombosis in pregnancy. BMJ. 
2017;357:j2344. doi: 10.1136/bmj.j2344 pmid: 28566284 
16. ACOG Practice Bulletin No. 196: Thromboembolism in 
Pregnancy. Obstet Gynecol. 2018;132(1):e1-e17. doi: 
10.1097/AOG.0000000000002706 pmid: 29939938 
17. Ray JG, Vermeulen MJ, Bharatha A, Montanera WJ, Park AL. 
Association Between MRI Exposure During Pregnancy and 
Fetal and Childhood Outcomes. JAMA. 2016;316(9):952-61. 
doi: 10.1001/jama.2016.12126 pmid: 27599330 
18. Chaturvedi S, McCrae KR. The antiphospholipid syndrome: 
still an enigma. Hematology Am Soc Hematol Educ Program. 
2015;2015:53-60. doi: 10.1182/asheducation-2015.1.53 
pmid: 26637701 
19. Chan WS, Rey E, Kent NE, Group VTEiPGW, Chan WS, Kent 
NE, et al. Venous thromboembolism and antithrombotic 
therapy in pregnancy. J Obstet Gynaecol Can. 
2014;36(6):527-53. doi: 10.1016/S1701-2163(15)30569-7 
pmid: 24927193 
20. Ormesher L, Simcox LE, Tower C, Greer IA. 'To test or not to 
test', the arguments for and against thrombophilia testing in 
obstetrics. Obstet Med. 2017;10(2):61-6. doi: 
10.1177/1753495X17695696 pmid: 28680464 
21. Rodger MA, Gris JC, de Vries JIP, Martinelli I, Rey E, 
Schleussner E, et al. Low-molecular-weight heparin and 
recurrent placenta-mediated pregnancy complications: a meta-
analysis of individual patient data from randomised controlled 
trials. Lancet. 2016;388(10060):2629-41. doi: 10.1016/S014 
0-6736(16)31139-4 pmid: 27720497 
22. Martens TZ, Emed JD. The experiences and challenges of 
pregnant women coping with thrombophilia. J Obstet Gynecol 
Neonatal Nurs. 2007;36(1):55-62. doi: 10.1111/j.1552-
6909.2006.00113.x pmid: 17238947 
23. Glover V. Maternal depression, anxiety and stress during 
pregnancy and child outcome; what needs to be done. Best 
Pract Res Clin Obstet Gynaecol. 2014;28(1):25-35. doi: 
10.1016/j.bpobgyn.2013.08.017 pmid: 24090740 
24. Fogerty AE. Management of Venous Thromboembolism in 
Pregnancy. Curr Treat Options Cardiovasc Med. 
2018;20(8):69. doi: 10.1007/s11936-018-0658-3 pmid: 
30039233 
25. Middeldorp S. New studies of low-molecular-weight heparin in 
pregnancy. Thromb Res. 2015;135 Suppl 1:S26-9. doi: 
10.1016/S0049-3848(15)50436-2 pmid: 25903529
 
 
